Karisa C Schreck

List of Publications by Year
in descending order

40 papers	1,546 citations	623188 14 h-index	414034 32 g-index
41 all docs	41 docs citations	41 times ranked	2774 citing authors

#	Article	IF	Citations
1	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. Expert Review of Anticancer Therapy, 2022, 22, 275-287.	1.1	3
2	Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene, 2022, 41, 2973-2983.	2.6	9
3	BIMG-23. SINGLE-VOXEL VERSUS MULTI-SLICE MRSI IN PATIENTS WITH GLIOMA ON A KETOGENIC DIET INTERVENTION. Neuro-Oncology Advances, 2021, 3, i6-i6.	0.4	0
4	DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS. Neuro-Oncology Advances, 2021, 3, i13-i13.	0.4	0
5	Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. Neurology, 2021, 97, e953-e963.	1.5	18
6	Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathology, 2021, 38, 228-233.	1.1	9
7	ECOA-10. Integrated genomic and clinical analysis of BRAF-mutated glioma in adults. Neuro-Oncology Advances, 2021, 3, ii3-ii3.	0.4	0
8	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
9	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
10	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 2021, 27, 6197-6208.	3.2	20
11	Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa138.	0.4	14
12	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice, 2020, 7, 369-375.	1.0	2
13	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	0.6	23
14	Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.. Journal of Clinical Oncology, 2020, 38, e14506-e14506.	0.8	1
15	PATH-26. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF BRAF-MUTATED GLIOMA IN ADULTS. Neuro-Oncology, 2020, 22, ii169-ii170.	0.6	0
16	DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN BRAF V600E HUMAN GLIOMA. Neuro-Oncology, 2020, 22, ii64-ii64.	0.6	0
17	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 2019, 11, 1262.	1.7	99
18	Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. Journal of Neuro-Oncology, 2019, 143, 87-93.	1.4	68

#	Article	IF	Citations
19	EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY. Neuro-Oncology, 2019, 21, vi90-vi90.	0.6	0
20	ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS. Neuro-Oncology, 2019, 21, vi23-vi23.	0.6	0
21	Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet. American Journal of Neuroradiology, 2019, 40, 1908-1915.	1.2	6
22	Effect of ketogenic diets on leukocyte counts in patients with epilepsy. Nutritional Neuroscience, 2019, 22, 522-527.	1.5	12
23	Concurrent BRAF/MEK Inhibitors in BRAF V600â€“Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 343-347.	2.3	46
24	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. Neuro-Oncology, 2018, 20, vi164-vi164.	0.6	2
25	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, 469-474.	0.6	34
26	Neurosarcoidosis Presenting With Recurrent Strokes. Neurohospitalist, The, 2017, 7, 91-95.	0.3	7
27	Clinical Reasoning: A 70-year-old woman with acute-onset weakness and progressive hemiataxia. Neurology, 2016, 87, e264-e268.	1.5	5
28	Clinical Reasoning: A 44-year-old woman with rapidly progressive weakness and ophthalmoplegia. Neurology, 2015, 85, e22-7.	1.5	2
29	Notch Signaling Activation in Pediatric Low-Grade Astrocytoma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 121-131.	0.9	6
30	Clinical response to bevacizumab in schwannomatosis. Neurology, 2014, 83, 1986-1987.	1.5	33
31	A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica, 2013, 126, 607-608.	3.9	9
32	Notch Signaling Promotes Growth and Invasion in Uveal Melanoma. Clinical Cancer Research, 2012, 18, 654-665.	3.2	63
33	Notch3 Activation Promotes Invasive Glioma Formation in a Tissue Site-Specific Manner. Cancer Research, 2011, 71, 1115-1125.	0.4	32
34	Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells. Cancer Research, 2011, 71, 1415-1415.	0.4	1
35	The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nature Neuroscience, 2010, 13, 551-558.	7.1	156
36	The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance. Clinical Cancer Research, 2010, 16, 6060-6070.	3.2	146

#	Article	IF	Citations
37	Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma. , 2010, , .		1
38	PML: a tumor suppressor essential for neocortical development. Nature Neuroscience, 2009, 12, 108-110.	7.1	6
39	Notch, Neural Stem Cells, and Brain Tumors. Cold Spring Harbor Symposia on Quantitative Biology, 2008, 73, 367-375.	2.0	66
40	Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. Stem Cells, 2007, 25, 2524-2533.	1.4	578